Literature DB >> 35643078

Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems.

Xinhong Chen1, Sripriya Ravindra Kumar1, Cameron D Adams2, Daping Yang3, Tongtong Wang1, Damien A Wolfe1, Cynthia M Arokiaraj1, Victoria Ngo4, Lillian J Campos5, Jessica A Griffiths1, Takako Ichiki1, Sarkis K Mazmanian1, Peregrine B Osborne2, Janet R Keast2, Cory T Miller4, Andrew S Fox5, Isaac M Chiu3, Viviana Gradinaru6.   

Abstract

Gene therapy offers great promise in addressing neuropathologies associated with the central and peripheral nervous systems (CNS and PNS). However, genetic access remains difficult, reflecting the critical need for the development of effective and non-invasive gene delivery vectors across species. To that end, we evolved adeno-associated virus serotype 9 (AAV9) capsid in mice and validated two capsids, AAV-MaCPNS1 and AAV-MaCPNS2, across rodent species (mice and rats) and non-human primate (NHP) species (marmosets and rhesus macaques). Intravenous administration of either AAV efficiently transduced the PNS in rodents and both the PNS and CNS in NHPs. Furthermore, we used AAV-MaCPNS1 in mice to systemically deliver the following: (1) the neuronal sensor jGCaMP8s to record calcium signal dynamics in nodose ganglia and (2) the neuronal actuator DREADD to dorsal root ganglia to mediate pain. This conclusively demonstrates the translatability of these two systemic AAVs across four species and their functional utility through proof-of-concept studies in mice. Published by Elsevier Inc.

Entities:  

Keywords:  AAV; CNS; PNS; cross-species; functional modulation; functional readout; gene therapy; non-human primate

Mesh:

Year:  2022        PMID: 35643078      PMCID: PMC9308721          DOI: 10.1016/j.neuron.2022.05.003

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   18.688


  78 in total

Review 1.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

2.  Sensory Neurons that Detect Stretch and Nutrients in the Digestive System.

Authors:  Erika K Williams; Rui B Chang; David E Strochlic; Benjamin D Umans; Bradford B Lowell; Stephen D Liberles
Journal:  Cell       Date:  2016-05-26       Impact factor: 41.582

3.  Retro-orbital injections in mice.

Authors:  Tal Yardeni; Michael Eckhaus; H Douglas Morris; Marjan Huizing; Shelley Hoogstraten-Miller
Journal:  Lab Anim (NY)       Date:  2011-05       Impact factor: 12.625

Review 4.  Adeno-Associated Virus Toolkit to Target Diverse Brain Cells.

Authors:  Rosemary C Challis; Sripriya Ravindra Kumar; Xinhong Chen; David Goertsen; Gerard M Coughlin; Acacia M Hori; Miguel R Chuapoco; Thomas S Otis; Timothy F Miles; Viviana Gradinaru
Journal:  Annu Rev Neurosci       Date:  2022-04-19       Impact factor: 15.553

5.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Authors:  Kevin D Foust; Emily Nurre; Chrystal L Montgomery; Anna Hernandez; Curtis M Chan; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

6.  Intracranial AAV-IFN-β gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model.

Authors:  Dwijit GuhaSarkar; James Neiswender; Qin Su; Guangping Gao; Miguel Sena-Esteves
Journal:  Mol Oncol       Date:  2017-01-18       Impact factor: 6.603

Review 7.  AAV Targeting of Glial Cell Types in the Central and Peripheral Nervous System and Relevance to Human Gene Therapy.

Authors:  Simon J O'Carroll; William H Cook; Deborah Young
Journal:  Front Mol Neurosci       Date:  2021-01-11       Impact factor: 5.639

Review 8.  Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB.

Authors:  Seigo Kimura; Hideyoshi Harashima
Journal:  Pharmaceutics       Date:  2020-12-15       Impact factor: 6.321

9.  Intraarticular Adeno-Associated Virus Serotype AAV-PHP.S-Mediated Chemogenetic Targeting of Knee-Innervating Dorsal Root Ganglion Neurons Alleviates Inflammatory Pain in Mice.

Authors:  Sampurna Chakrabarti; Luke A Pattison; Balint Doleschall; Rebecca H Rickman; Helen Blake; Gerard Callejo; Paul A Heppenstall; Ewan St John Smith
Journal:  Arthritis Rheumatol       Date:  2020-08-11       Impact factor: 10.995

10.  Gene therapy for spinal muscular atrophy: the Qatari experience.

Authors:  Hossamaldein Gaber Ali; Khalid Ibrahim; Mahmoud Fawzi Elsaid; Reem Babiker Mohamed; Mahmoud I A Abeidah; Azhar Othman Al Rawwas; Khaled Elshafey; Hajer Almulla; Karen El-Akouri; Mariam Almulla; Amna Othman; Sara Musa; Fatma Al-Mesaifri; Rehab Ali; Noora Shahbeck; Mariam Al-Mureikhi; Reem Alsulaiman; Saad Alkaabi; Tawfeg Ben-Omran
Journal:  Gene Ther       Date:  2021-07-19       Impact factor: 5.250

View more
  2 in total

Review 1.  Non-coding RNAs: Important participants in cardiac fibrosis.

Authors:  Yiheng Dong; Naling Peng; Lini Dong; Shengyu Tan; Xiangyu Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-28

2.  Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders.

Authors:  Jihad El Andari; Edith Renaud-Gabardos; Warut Tulalamba; Jonas Weinmann; Louise Mangin; Quang Hong Pham; Susanne Hille; Antonette Bennett; Esther Attebi; Emanuele Bourges; Christian Leborgne; Nicolas Guerchet; Julia Fakhiri; Chiara Krämer; Ellen Wiedtke; Robert McKenna; Laurence Guianvarc'h; Magali Toueille; Giuseppe Ronzitti; Matthias Hebben; Federico Mingozzi; Thierry VandenDriessche; Mavis Agbandje-McKenna; Oliver J Müller; Marinee K Chuah; Ana Buj-Bello; Dirk Grimm
Journal:  Sci Adv       Date:  2022-09-21       Impact factor: 14.957

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.